Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3535 - Integrative analysis of NSCLC identifies tumor genetic profiles associated with PD-L1 expression.

Date

11 Sep 2017

Session

Poster display session

Topics

Translational Research;  Thoracic Malignancies

Presenters

Maria Saigi Morgui

Authors

M. Saigi Morgui1, C. Pereira1, E. Pros1, E. Brambilla2, J. Alburquerque1, N. Baixeras3, M. Sánchez-Céspedes1, E. Nadal4

Author affiliations

  • 1 Cancer Epigenetics And Biology Program, IDIBELL, 08907 - Hospitalet de Llobregat/ES
  • 2 Pathology Department, CHU Grenoble - Hopital Michallon, 38043 - La Tronche/FR
  • 3 Pathology Department, Hospital de Bellvitge-ICO, 08907 - Hospitalet de Llobregat/ES
  • 4 Thoracic Oncology Unit, Institut Catala d'Oncologia ICO, 08907 - Hospitalet de Llobregat/ES
More

Resources

Abstract 3535

Background

PD-L1 expression is associated with clinical benefit from anti-PD1/anti-PD-L1 therapies in advanced NSCLC. However, additional biomarkers are needed to predict which patients will benefit most. The aim of this study is to correlate specific genomic alterations with immunological biomarkers in a cohort of NSCLC.

Methods

Patients diagnosed with NSCLC from 2000 to 2005 were retrospectively reviewed. Genetic mutations and copy number of selected genes were determined by Sanger and FISH. Immunophenotype was defined by PD-L1, HLA-1 and TILs CD8+ immunostaining and scored as follows: PD-L1 positivity ≥ 5% on membrane tumor cells; HLA-1 intensity: 0+,1+,2+; TILs CD8+ score: low or high infiltration. Statistical analysis using Chi-square test and logistic regression were performed.

Results

From 150 patients: 87% males; stage: 90% I-II, 10% III-IV; histology: 42% adenocarcinoma (ADC), 44% squamous (SCC), 14% sarcomatoid carcinoma (SaC). Genomic alterations according to histologic subtype are summarized in table 1. PD-L1 was positive in 47% of tumors (49% of ADC, 43% of SCC, 58% of SaC), and correlated with TILs CD8+ (p <.001) and HLA-1 (p=.002). PD-L1 positivity was associated with MET alterations (4.5% MET amp, 2% METexon14 skipping), OR=5.4 (1.4-21.2), p=.015. ADC harbouring STK11 loss of function were correlated with negative PD-L1 (p = .01) and associated with immunosupressive phenotype (negative PD-L1, low CD8+), OR=11.6 (2.1-64), p=.005. Distinct PD-L1 expression was evidenced in KRAS mutant tumors according to additional co-mutations: 25% of KRAS+STK11 were PD-L1+ whereas 75% of KRAS+TP53 were PD-L1+, despite no statistically significance.

Table 1. Genetic alterations according to histologic subtype (N=150).
ADC n= 59 (100%) SCC n= 62 (100%) SaC n=19 (100%)
KRAS MET amp METex14
mut (exons 2-3) 14 (20%) GA 3 (5%) Mut 1 (5%)
wt 45 (80%) NC 53 (85%) wt 16 (94%)
Unknown 6 (10%) Unknown 2 (1)
EGFR METex14 KRAS
mut (exon18-21) 6 (10) Mut 0 Mutation 4 (21)
wt 49 (83) wt 58 (94) wt 12 (63)
Unknown 4 (7) Unknown 4 (6) Unknown 3 (16)
ALK PIK3CA amp STK11
Transloc. 1 (2) GA 6 (10) Mutation 1 (5)
wt 57(96) NC 20 (32) wt 15 (79)
Unknown 1 (2) Unknown 36 (58) Unknown 3 (16)
STK11 FGFR1 amp
mut 10 (17) Amp 9 (15)
wt 46 (78) NA 51 (82)
Unknown 3 (5) Unknown 2 (3)
METex14
Mut 2 (3)
wt 50 (95)
Unknown 7 (12)
MET amp
GA 4 (7)
wt 51 (86)
Unknown 4 (7)
Co-mutation KRAS+STK11
Mut 4 (7)
wt 55 (93)
Co-mutation KRAS+P53
Mut 4 (7)
wt 54 (91)
Unknown 1 (2)

Conclusions

MET and STK11 alterations were correlated with differential expression of tumor PD-L1. STK11 mutant tumors were more likely to have an immunosupressive phenotype. Tumors harbouring specific genomic alterations might be enriched for distinct immunophenotypes which might contribute to rational use of immunotherapies.

Clinical trial identification

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.